期刊
MEDICAL ONCOLOGY
卷 39, 期 5, 页码 -出版社
HUMANA PRESS INC
DOI: 10.1007/s12032-022-01677-0
关键词
Cancer therapy; Novel therapy; Immunotherapy; Regulatory challenges
类别
Cancer therapy has undergone a significant revolution with the introduction of novel therapies, addressing the limitations of conventional treatments and improving patient survival. However, the emergence of these therapies has raised various clinical, ethical, and regulatory concerns.
Cancer therapy has undergone a drastic revolution in the past few decades with the introduction of several novel therapies, like immunotherapy (active and passive), stem cell-based therapies, and nanocarrier-based therapies. These therapies have addressed the issues of conventional cancer therapy (chemotherapy or radiotherapy), like specificity and off-target effects. Further, the introduction of such treatments has improved survival and converted a terminal disease into a more manageable condition. However, many clinical, ethical, and regulatory issues are raised with such novel additions. Several effective therapies are under research but could not come to market or are delayed due to regulatory concerns for marketing approval. The scope of this review encompasses the examination of these regulatory issues and discuss their possible solutions. A practical and flexible regulatory approach, harmonized globally, could help the patients suffering from a terminal illness to lead a quality life.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据